Article Information
History
- September 25, 2021.
Article Versions
- You are currently viewing Version 1 of this article (September 25, 2021 - 15:27).
- Version 2 (February 23, 2022 - 23:01).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Hideyuki Shimizu1,2,3,*,
- Manabu Kodama1,
- Masaki Matsumoto4,
- Yasuko Orba5,
- Michihito Sasaki5,
- Akihiko Sato5,6,
- Hirofumi Sawa5,7,8,9 and
- Keiichi I. Nakayama1,*
- 1Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
- 2Department of Systems Biology, Harvard Medical School, Boston, MA, USA
- 3Wyss Institute for Biologically Inspired Engineering, Harvard Medical School, Boston, MA, USA
- 4Department of Omics and Systems Biology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 5Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
- 6Drug Discovery and Disease Research Laboratory, Shionogi & Co. Ltd., Osaka, Japan
- 7International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
- 8One Health Research Center, Hokkaido University, Sapporo, Japan
- 9Global Virus Network, Baltimore, MD, USA
- ↵*Correspondence: hideyuki_shimizu{at}hms.harvard.edu (H.S.) or nakayak1{at}bioreg.kyushu-u.ac.jp (K.I.N.)
Posted September 25, 2021.
LIGHTHOUSE illuminates therapeutics for a variety of diseases including COVID-19
